臨床整形外科51巻7号

2016年07月発行

誌上シンポジウム 脊椎腫瘍 最近の話題

原発性脊椎腫瘍の治療における最近の進歩

著者： 上井浩¹ 德橋泰明¹ 吉田行弘¹

所属機関： ¹日本大学医学部整形外科学系整形外科学分野

ページ範囲：P.593 - P.599

　切除困難な脊椎骨巨細胞腫の治療は，デノスマブ投与による腫瘍の縮小化により，手術のダウンステージングや根治的手術の可能性が高まった．また，仙骨脊索腫の治療では，重粒子線治療は良好な局所制御率を認め，治療後の身体的機能の維持にも優れており，標準的治療になりつつある．動脈瘤様骨囊腫の治療はscleroplastyやsacroplasty，デノスマブ投与などが行われ始めた．いずれの治療法も健康関連QOL(HRQOL)を考慮した低侵襲の治療に移行してきたといえるが，長期経過後の成績が不確定であり，今後の経過をみる必要がある．

参考文献

1) 日本整形外科学会骨軟部腫瘍委員会：全国骨腫瘍登録一覧表　平成24年度．国立がん研究センター，2012.

2) Unni KK. Dahlin's Bone Tumors:General Aspects and Data on 10,165 Cases. 6th ed. New York, Lippincott Williams ＆ Wilkins, 225-242, 2010.

3) Refai D, Dunn GP, Santiago P, et al. Giant cell tumor of the thoracic spine:case report and review of the literature. Surg Neurol 2009;71:228-33.

4) Elder BD, Sankey EW, Goodwin CR, et al. Surgical outcomes in patients with high spinal instability neoplasm score secondary to spinal giant cell tumors. Global Spine J 2016;6(1):21-8.

5) Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone:interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013;14:901-8.

6) Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone:an open-label, phase 2 study. Lancet Oncol 2010;11:275-80.

7) Rutkowski P, Ferrari S, Grimer RJ, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 2015;22:2860-8.

8) Ueda T, Morioka MY, Nishida S, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone:a multicenter phase II trial. Ann Oncol 2015;10:2149-54.

9) Bjornsson J, Wold LE, Ebersold MJ, et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer 1993;71:735-40.

10) Stener B, Gunterberg B. High amputation of the sacrum for extirpation of tumors. Principles and technique. Spine 1978;3:351-66.

11) McPherson CM, Suki D, McCutcheon IE, et al. Metastatic disease from spinal chordoma:a 10-year experience. J Neurosurg Spine 2006;5:277-80.

12) Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma:natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003;10:291-6.

13) Nishida Y, Kamada T, Imai R. Clinical outocome of sacral chordoma with carbon ion therapy compared with surgery. Int J Radiation Oncology Biol Phys 2011;79:110-6.

14) Imai R, Kamada T, Sugahara S, et al:Carbon ion radiotherapy for sacral chordoma. Br J Radiol 2011;84:S48-S54.

15) Stacchiotti S, Sommer J. Chordoma Global Consensus Group:Building a global consensus approach to chordoma:a position paper from the medical and patient community. Lancet Oncol 2015;16:e71-83.

16) Tsagozis P, Brosjö O. Current strategies for the treatment of aneurysmal bone cysts. Orthop Rev (Pavia) 2015:7:6182, doi:http://dx.doi.org/10.4081/or.2015.6182, 2015.

17) Skubitz KM, Peltola JC, Santos ER. Response of aneurysmal bone cyst to denosumab. Spine 2015;40:E1201-4. doi:10.1097/BRS.0000000000001027.

18) Batisse F, Schmitt A, Vendeuvre T, et al. Aneurysmal bone cyst:A 19-case series managed by percutaneous sclerotherapy. Orthop Traumatol Surg Res. doi:10.1016/j.otsr.2015.11.016 [Epub ahead of print], 2016.

19) Nas OF, Kaçar E, Buyukkaya R, et al. Treatment of sacral aneurysmal bone cyst with percutaneous sacroplasty. Spine J 2016;16:e1-2, doi:10.1016/j.spinee.2015.08.005. [Epub ahead of print], 2016.

20) Charest-Morin R, Dea N, Fisher CG. Health-related quality of life after spine surgery for primary bone tumour. Curr Treat Options Oncol 2016;17:9. doi:10.1007/s11864-015-0383-z.